AI Engines For more Details: Perplexity Kagi Labs You
Vascular Conditions: Ethaverine acts as a vasodilator, meaning it helps widen blood vessels. This effect can be beneficial in conditions where there is restricted blood flow due to spasms or constriction of blood vessels. It may be used to alleviate symptoms associated with peripheral vascular disease or Raynaud's phenomenon.
Gastrointestinal Disorders: Ethaverine's antispasmodic properties make it useful in treating conditions characterized by smooth muscle spasms in the gastrointestinal tract. These conditions may include irritable bowel syndrome (IBS), functional dyspepsia, and other gastrointestinal motility disorders. By reducing smooth muscle contractions, it can relieve symptoms such as abdominal pain and cramping.
Urinary Disorders: Ethaverine may also be used to alleviate symptoms of urinary disorders caused by smooth muscle spasms in the urinary tract. Conditions such as urinary urgency and frequency associated with conditions like interstitial cystitis may benefit from its antispasmodic effects.
Other Uses: Ethaverine has also been investigated for its potential use in the treatment of erectile dysfunction (ED) due to its ability to relax smooth muscles. However, its efficacy for this purpose may vary, and other medications are more commonly prescribed for ED.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 3.7 | 0.3 | 11.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 1.5 | 0.53 |
| Allergies | 4 | 2.6 | 0.54 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.6 | 6 | -0.3 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 0.3 | 7.67 |
| Ankylosing spondylitis | 3.1 | 1 | 2.1 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 4 | 1.8 | 1.22 |
| Atherosclerosis | 1.7 | 2.2 | -0.29 |
| Atrial fibrillation | 3.7 | 2.2 | 0.68 |
| Autism | 7 | 7.8 | -0.11 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 1.5 | 1.1 | 0.36 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 0.3 | 1.8 | -5 |
| Carcinoma | 3.2 | 2.6 | 0.23 |
| Celiac Disease | 2.6 | 2.9 | -0.12 |
| Cerebral Palsy | 1.1 | 1.3 | -0.18 |
| Chronic Fatigue Syndrome | 3.2 | 6.6 | -1.06 |
| Chronic Kidney Disease | 2.8 | 2.9 | -0.04 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.4 | 0.21 |
| Chronic Urticaria (Hives) | 0.5 | 0.9 | -0.8 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 5.6 | 2.2 | 1.55 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.3 | 2.7 | -1.08 |
| COVID-19 | 7.1 | 11 | -0.55 |
| Crohn's Disease | 6.6 | 5.5 | 0.2 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.6 | -1.6 | |
| deep vein thrombosis | 1.8 | 1.4 | 0.29 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 8.5 | 7.7 | 0.1 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.6 | 2.2 | -2.67 |
| Endometriosis | 2.3 | 1.7 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.4 | 1.7 | 0.41 |
| erectile dysfunction | 0.6 | 0.3 | 1 |
| Fibromyalgia | 2.8 | 2.2 | 0.27 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 4.3 | 0.12 |
| gallstone disease (gsd) | 2.3 | 0.8 | 1.87 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.2 | -0.09 |
| Generalized anxiety disorder | 1.1 | 1.4 | -0.27 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 0.8 | 0.63 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 1.4 | -0.56 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 3.3 | 1.8 | 0.83 |
| Heart Failure | 2.7 | 1.9 | 0.42 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.5 | 1.1 | -1.2 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.1 | 4.8 | -0.17 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 2.4 | 0.6 | 3 |
| IgA nephropathy (IgAN) | 1.3 | 3.7 | -1.85 |
| Inflammatory Bowel Disease | 4.8 | 8.1 | -0.69 |
| Insomnia | 2.1 | 2.1 | 0 |
| Intelligence | 1.3 | 0.3 | 3.33 |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 5.4 | 4.8 | 0.13 |
| ischemic stroke | 1.7 | 1.1 | 0.55 |
| Liver Cirrhosis | 5.3 | 3.1 | 0.71 |
| Long COVID | 4.9 | 7.6 | -0.55 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 1 | -0.67 |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 0.5 | 2.4 | -3.8 |
| ME/CFS without IBS | 0.6 | 2.4 | -3 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.1 | 0.5 | 1.2 |
| Metabolic Syndrome | 5.9 | 5.9 | 0 |
| Mood Disorders | 7.9 | 6.5 | 0.22 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.4 | 6.6 | -0.22 |
| Multiple system atrophy (MSA) | 0.6 | 0.7 | -0.17 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 1.8 | -1.8 | |
| Neuropathy (all types) | 0.4 | 1.3 | -2.25 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 4 | 0 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 7.4 | 6.2 | 0.19 |
| obsessive-compulsive disorder | 4.8 | 3.5 | 0.37 |
| Osteoarthritis | 1.6 | 1.2 | 0.33 |
| Osteoporosis | 1.3 | 1.3 | 0 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.9 | 5.6 | 0.23 |
| Polycystic ovary syndrome | 6.4 | 3.2 | 1 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.3 | -0.44 |
| Primary sclerosing cholangitis | 1.8 | 2.7 | -0.5 |
| Psoriasis | 3 | 3.1 | -0.03 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.3 | 4 | 0.57 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 4.8 | 2.8 | 0.71 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 1.5 | 2.9 | -0.93 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 2.3 | 2.1 | 0.1 |
| Systemic Lupus Erythematosus | 2.9 | 1.8 | 0.61 |
| Tic Disorder | 1.5 | 1.5 | 0 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.4 | 3.1 | 0.1 |
| Type 2 Diabetes | 6.8 | 6 | 0.13 |
| Ulcerative colitis | 4.3 | 6.1 | -0.42 |
| Unhealthy Ageing | 3.8 | 2.4 | 0.58 |
| Vitiligo | 2.4 | 1.5 | 0.6 |
